Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 24:353:i2607.
doi: 10.1136/bmj.i2607.

Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study

Shirley V Wang  1 , Jessica M Franklin  2 , Robert J Glynn  2 , Sebastian Schneeweiss  2 , Wesley Eddings  2 , Joshua J Gagne  2
Affiliations

Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study

Shirley V Wang et al. BMJ. .

Abstract

Objectives: To compare stratified event rates from randomized controlled trials with predicted event rates from models developed in observational data, and assess their ability to accurately capture observed rates of thromboembolism and major bleeding for patients treated with dabigatran or warfarin as part of routine care.

Design: New initiator cohort study.

Setting: Data from United Health (October 2009 to June 2013), a commercial healthcare claims database in the United States.

Participants: 21 934 adults with atrial fibrillation initiating dabigatran (150 mg dose only) or warfarin treatment as part of routine care.

Main outcome measures: Predicted annual rates of thromboembolism or major bleeding, based on estimates from randomized controlled trials, models developed in routine care patients, and baseline risk scores (CHADS2, CHA2DS2-VASc, and HAS-BLED). Thromboembolism was a composite outcome, including primary inpatient diagnosis codes for ischemic or ill defined stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis, and systemic embolism. Major bleeding was a composite outcome including codes occurring in an inpatient setting for hemorrhagic stroke; major upper, lower, or unspecified gastrointestinal bleed; and major urogenital or other bleed.

Results: 6516 (30%) and 15 418 (70%) of patients initiated dabigatran and warfarin, respectively. Annual event rates per 100 patients were 1.7 for thromboembolism and 4.6 for major bleeding. For thromboembolism, calibration of estimates from randomized controlled trials was similar to calibration for model based predictions; however, trial estimates for major bleeding consistently underestimated the rate of bleeding among patients in routine care. Underestimation of bleeding rates was particularly pronounced in warfarin initiators with high HAS-BLED scores, where event rates were underestimated by up to 4.0 per 100 patient years. Harrell's c indices for discrimination for thromboembolism or major bleeding in dabigatran and warfarin initiators ranged between 0.59 and 0.66 for randomized controlled trial predictions, and between 0.52 and 0.70 for cross validated model based predictions.

Conclusion: Estimated rates of thromboembolism under dabigatran or warfarin treatment in randomized controlled trials were close to observed rates in routine care patients. However, rates of major bleeding were underestimated. Models developed in routine care patients can provide accurate, tailored estimates of risk and benefit under alternative treatment to enhance patient centered care.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from the Agency for Healthcare Research and Quality for the submitted work; SVW, JF, and JJG are paid consultants to Aetion, a software company; SS is principal investigator of the Harvard-Brigham Drug Safety and Risk Management Research Center funded by US Food and Drug Administration (FDA)—his work is partly funded by grants or contracts from the Patient-Centered Outcomes Research Institute, FDA, and National Heart, Lung, and Blood Institute; SS is consultant to WHISCON (World Health Information Science Consultants) and to Aetion, a software manufacturer of which he also owns equity; SS is principal investigator of investigator initiated grants to the Brigham and Women’s Hospital from Novartis and Boehringer Ingelheim unrelated to this study; no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Steps for obtaining predicted annual rates per 100 patient years of thromboembolism and major bleeding outcomes from randomized controlled trial participants and routine care patients. *Risk score=estimated baseline rate of outcome from relevant external risk score developed in patients not on oral anticoagulation therapy (or mix of treated and untreated). Risk score factors are CHADS2 (congestive heart failure, hypertension, age≥75 years, diabetes mellitus, previous stroke/transient ischaemic attack/thromboembolism (doubled risk weight)), CHA2DS2-VASc (CHADS2 plus vascular disease, age 65-74 years, and female sex (age≥75 years and previous stroke carry doubled risk weight)), and HAS-BLED (age>65 years, hypertension, abnormal renal function, abnormal liver function, prior stroke, bleeding history (or predisposition), drugs predisposing to bleed, alcohol use disorders, and labile international normalized ratio). †Estimated rate of outcomes in trial participants randomized to warfarin or dabigatran. ‡Estimated rate of outcomes from models fit separately in initiators of warfarin and dabigatran in routine care, using risk factors in relevant risk score. Performance evaluated for average estimate from repeated 10-fold cross validation
None
Fig 2 Calibration of predicted rates per 100 patient years of thromboembolism or major bleeding in initiators of dabigatran or warfarin. Difference between rates calculated as observed rates minus predicted rates. RCT=estimated rate of outcomes in trial participants randomized to warfarin or dabigatran; model=estimated rate of outcomes from models fit separately in initiators of warfarin and dabigatran in routine care, using risk factors in relevant risk score; score=estimated baseline rate of outcome from relevant external risk score developed in patients not on oral anticoagulation therapy (or mix of treated and untreated patients). Performance evaluated for average estimate from repeated 10-fold cross validation. Risk score factors: CHADS2=congestive heart failure, hypertension, age (≥75 years), diabetes mellitus, and previous stroke/transient ischaemic attack/thromboembolism (doubled risk weight); CHA2DS2-VASc=factors in CHADS2 plus vascular disease, age 65-74 years, and female sex (age≥75 years and previous stroke carry doubled risk weight); HAS-BLED=age>65 years, hypertension, abnormal renal and liver function, prior stroke, bleeding history (or predisposition), drugs predisposing to bleed, alcohol use disorders, and labile international normalized ratio. Criteria for ascertaining major bleeding in clinical trials: ISTH=International Society on Thrombosis and Haemostasis; TIMI=thrombolysis in myocardial infarction; GUSTO=global use of strategies to open occluded arteries
See this image and copyright information in PMC

References

    1. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72. 10.1378/chest.09-1584 pmid:19762550. - DOI - PubMed
    1. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100. 10.1378/chest.10-0134 pmid:20299623. - DOI - PubMed
    1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. 10.1056/NEJMoa0905561 pmid:19717844. - DOI - PubMed
    1. Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92. 10.1056/NEJMoa1107039 pmid:21870978. - DOI - PubMed
    1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67. 10.7326/0003-4819-146-12-200706190-00007 pmid:17577005. - DOI - PubMed

MeSH terms